

Index

Page numbers in *italics* refer to illustrations; those in **bold** refer to tables

A

ABO blood group system 152–153, **153**
activated partial thromboplastin time (APTT) 140, 141
activated protein C (APC) 139, 148, *148*
 resistance to 148–149
acute lymphoblastic leukaemia (ALL) 89–90, *89*
acute myeloid leukaemia (AML) 105, 106–109, **106**, *107, 108*
 therapy-related 108
acute promyelocytic leukaemia (APML) 108–109
adult T-cell leukaemia/lymphoma (ATLL) 72
all-*trans* retinoic acid (ATRA) treatment 109
amyloid 102–103
amyloidosis 99, 102–103
anaemia 11–26
 aplastic 125–128
 macrocytic **13**, 21–26
 B12 and folate deficiency 21–25, 32
 megaloblastic 21–25, 32
 normoblastic 25–26
 microcytic 13–20, **13, 14**
 iron deficiency 13–19
 morphological classification 13, **13**
 normocytic **13**, 20–21
 anaemia of chronic disease (ACD) 20
 refractory (RA) 110
 with excess blasts (RAEB) 110
 with ring sideroblasts (RARS) 110
 see also aplastic anaemia; haemolytic anaemia; sickle cell anaemia
anticoagulant drugs 146–147
antiglobulin test 38, 154
antiphospholipid syndrome 149
antithrombin 148, *148*
aplastic anaemia 125–128, *126, 127*
apparent polycythaemia 113
Auer rods 107, *107*
autoimmune haemolytic anaemia (AIHA) 36, 37–39
 cold haemagglutinin disease 38–39, 39
 warm AIHA 37–38

B

B cells 65–69
 development 7, **8, 66**
 selection 70
 signalling 78
 inhibitors 77, 78
basophilia 56, 58
basophils 5, **9**
Bence-Jones proteins 100
benign paraproteinaemia 102
Bernard-Soulier disease 138
bleeding time test 134
blood transfusion 151–152
 antiglobulin test 154
 cross-matching and compatibility 153–154
 cryoprecipitate 157
 fresh-frozen plasma (FFP) 156–157
 granulocytes 157
 hazards of 157–161, *157*
 acute lung injury 160
 circulatory overload 160–161
 citrate toxicity 161
 graft-versus-host disease 160
 haemolytic reactions 158
 immediate-type hypersensitivity 160
 infection transmission 158–160
 management of reactions 161
 massive transfusion 161–162
 obtaining compatible blood 154
 platelets 138, 157
 red blood cells 152–154
bone marrow 1–9
 acute myeloid leukaemia 107
 aplastic anaemia 126–127, *126, 127*
 chronic myeloid leukaemia 111
 essential thrombocythaemia 116
 haemolysis 28–29, 29
 iron deficiency 19, 19
 lymphoma 76
 myelodysplasia 110
 myelofibrosis 114
 plasma cell myeloma 98, 99

- bone marrow transplantation 109, 117–123
 - allogeneic 117–121, 118
 - complications 119, 120
 - haploidentical transplant 121
 - immunosuppression 119–120
 - reduced intensity conditioning transplant 121
 - stem cell source 119
- autologous 117, 118, 121–122, 122, 123
- indications 117
- Burkitt lymphoma 72, 72, 95–96

C

- chronic lymphocytic leukaemia (CLL) 69, 90–92, 91
- chronic myeloid leukaemia (CML) 111–113, 111, 112
- chronic myelomonocytic leukaemia (CMML) 110
- circulatory overload following transfusion 160–161
- citrate toxicity 161
- clonality studies 167–168, 167
- coagulation pathway 138–140, 138, 139
 - acquired disorders 145–146
 - congenital disorders 141–145
 - tests for clotting defects 140–141
- cobalamin *see* vitamin B12
- cold haemagglutinin disease 38–39, 39
- cryoprecipitate 157
- cytogenetic analysis 90, 93, 95, 100, 111, 163–165, 164
- cytomegalovirus (CMV) infection 62–63
 - following bone marrow transplantation 120
 - transfusion-transmitted infection 159

D

- Diamond–Blackfan anaemia 128
- diffuse large B-cell lymphoma (DLBCL) 72, 73, 94–95, 96
- disseminated intravascular coagulation (DIC) 106, 108–109, 145–146
- Döhle bodies 57, 57
- dyskeratosis congenita 128

E

- ecchymoses 132, 133
- eosin-5-maleamide (EMA) binding test 32
- eosinophilia 56–58
- eosinophils 4–5, 9
- Epstein–Barr virus (EBV) infection 61–62, 62
 - Burkitt lymphoma association 71–72
 - immune response 61–62, 62
- erythrocytosis (*see also polycythaemia*) 26
- erythropoiesis 6–7, 12–13
- erythropoietin (EPO) 7, 113
- essential thrombocythaemia 115–116
- extranodal marginal zone lymphomas 96

F

- factor IX deficiency 144
- factor V Leiden 148–149
- factor VIII deficiency 141–143
 - autoantibody-mediated 146
- Fanconi anaemia 128
- ferritin 14, 18
 - iron deficiency diagnosis 18–19, 18
- fibrin 139
 - degradation products (FDPs) 140
- fibrinolytic mechanism 140, 140
- flow cytometry 59, 59–61, 60, 107, 108
- fluorescence *in situ* hybridization (FISH) 165, 165
- folate 21, 23
 - deficiency 21–25, 23, 32
- follicular lymphoma 92–93
- fresh-frozen plasma (FFP) 156–157

G

- gene expression profiling 72, 73
- glandular fever *see* infectious mononucleosis
- Glanzmann disease 138
- glucose-6-phosphate dehydrogenase (G6PD) deficiency 33–36, 35
- graft-versus-host disease (GVHD) 120
 - prevention 119–120
 - transfusion-associated 160
- graft-versus-leukaemia (GVL) effect 117–118, 120–121
- granulocytes 3–5, 9
 - abnormalities 57
 - transfusion 157

H

- haemarthrosis 143
- haematopoiesis 1–3, 2
- haematopoietic stem cells 1–3
 - transplantation 47, 117, 119, 121
- haemoglobin 41–43
 - defects 36
 - reference ranges 12
 - structural variants 47–54, 48
 - haemoglobin C 54, 54
 - haemoglobin E 53–54
 - haemoglobin S 48, 50
 - see also* sickle cell anaemia
- haemoglobin H disease (HbH) 44, 44, 45
- haemolysis 27–40, 29, 29
- haemolytic anaemia 27–40, 31
 - congenital 30–36
 - drug-induced 37, 40
 - immune 36–39, 39
 - non-immune 39–40, 40

haemolytic disease of the newborn (HDN) 154–156
 haemophilia A 141–143
 haemophilia B 144
 haemostasis 131–149
 classification of defects 132
 investigation of bleeding abnormalities 147–148
 hairy cell leukaemia 93–94, 95
 hand-foot syndrome 50, 51
 haptoglobin 28
 HbBart's hydrops fetalis syndrome 44–45
 heavy chain disease 103
 Heinz bodies 35, 35
Helicobacter pylori 72
 heparin 146–147
 heparin-induced thrombocytopenia (HIT) 137
 hepatitis E 159
 hepcidin 15, 15–16
 hereditary elliptocytosis (HE) 33, 33
 hereditary haemochromatosis 16
 hereditary haemorrhagic telangiectasia 134, 134
 hereditary persistence of fetal haemoglobin (HPFH)
 52–53
 hereditary pyropoikilocytosis 33
 hereditary spherocytosis (HS) 30–33, 32
HFE haemochromatosis 16
 HIV infection 63, 137, 142
 HIV-related lymphoma 96
 Hodgkin lymphoma 71, 76, **82**, 85–89
 nodular lymphocyte predominant 85
 nodular sclerosis 85, 86
 Reed–Sternberg cells 71, 72, 85–86, 86
 staging 87, **88**
 treatment 87–88
 see also lymphomas
 Howell–Jolly bodies 14, 25
 human T-cell leukaemia virus 1 (HTLV-1) 72
 hypercalcaemia 99
 hypersensitivity reactions following transfusion 160
 hypersplenism 40
 hyperviscosity syndrome 99, 99
 hypogammaglobulinaemia 91
 hypoxia inducible factor (HIF-1) 7, 15

I
 immune thrombocytopenic purpura (ITP) 132, 133,
 135–137
 see also thrombocytopenia
 immunoglobulins 66–70, 68
 gene rearrangement 68, 70
 immunophenotyping 75, 76, 107, 163
 immunosuppression, bone marrow transplantation
 119–120
 infectious mononucleosis 61–63, 61
 immune response 61–62, 62

integrated haematology laboratory report 171
 iron absorption 14–16
 iron deficiency anaemia 13–19, 17
 causes of deficiency 16–17
 diagnosis 18–19, 18, 19
 treatment 19
 iron overload 16
 thalassaemia major 46–47

L

lactate dehydrogenase (LDH) 28, 76
 leucocytosis 56–58, 57
 leucoerythroblastic reaction 63
 leucopenia 55–56
 leukaemias
 acute lymphoblastic (ALL) 89–90, 89
 acute myeloid (AML) 105, 106–109
 acute promyelocytic (APML) 108–109
 adult T-cell leukaemia/lymphoma (ATLL) 72
 chronic lymphocytic (CLL) 69, 90–91, 91
 chronic myeloid (CML) 111–113
 chronic myelomonocytic (CMML) 110
 hairy cell 93–94, 95
 versus lymphomas 71
 lymph nodes 65–66, 67
 Hodgkin lymphoma **86**, 87
 lymphoblastic lymphoma 90
 lymphocyte-depleted Hodgkin lymphoma 85
 lymphocytes 9, **9**
 precursors 8–9
 see also B cells; T cells
 lymphocytosis 58–59
 lymphoid lineage 2, 3
 lymphomas 69, 71–79
 see Hodgkin lymphoma; non-Hodgkin lymphoma
 classification 81
 high- and low-grade 73, **73**, 74
 immunophenotyping 75, 76
 molecular genetics 72–73, 72
 prognosis 77, **77**, 78, 83
 staging 76, **76**, 77, 87, **88**
 restaging during treatment 79
 treatment and management 77–79
 lymphopenia 58
 lymphoplasmacytic lymphoma 92
 lymphopoiesis 7–9

M

macrocytic anaemia **13**, 21–26
 macrophages 5, **9**
 major histocompatibility complex (MHC) 70
 malaria 40, 160

MALT lymphomas 96
 mantle cell lymphoma 69, 93, 94
 megakaryocytes 5, 5, 105
 absence 135
 megaloblastosis 21–25
 metamyelocytes, giant 24, 25
 microcytic anaemia 13–20, **13**, 14
 molecular genetics 165–171
 clonality studies 167, 167–168
 common gene mutations **165**
 next-generation sequencing 169–171, 170
 personalized medicine 171
 polymerase chain reaction (PCR) 166–167, 166
 monoclonal gammopathy of undetermined significance (MGUS) 97, 101, **102**, **102**
 monocytes 5, **9**, 105
 monocytopoiesis 5
 monocytosis 56, 58
 mucosa-associated lymphoid tissue (MALT) lymphomas 96
 mycosis fungoides 96
 myeloblasts 3, 4, 105
 myelodysplastic syndromes (MDS) 105, 109–110
 myelofibrosis 114–115, 114, 115
 myeloid cells 105
 myeloid lineage 2, 3
 myeloma 97, **102**
 see also plasma cell myeloma
 myelopoiesis 3–7
 myeloproliferative disorders 105, 111–116

N

natural killer (NK) cells 8, 65, **66**, 70
 neutropenia 55–56
 neutrophils 3–4, 4, 5, **9**, 105
 hypogranular 110
 inherited abnormalities 57, **58**
 neutrophil leucocytosis 56–57, 57
 next-generation sequencing 169–171, 170
 nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) 85
 nodular sclerosis Hodgkin lymphoma 85, 86
 non-Hodgkin lymphoma 71, 76, 89–96
 B-cell **84**
 Burkitt lymphoma 72, 72, 95–96
 diffuse large B-cell lymphoma (DLBCL) 72–73, 73, 94–95, 96
 extranodal marginal zone lymphomas 96
 follicular lymphoma 92–93
 HIV-related lymphoma 96
 lymphoblastic lymphoma 90
 lymphoplasmacytic lymphoma 92
 mantle cell lymphoma 69, 93, 94
 small lymphocytic lymphoma (SLL) 91, 92
 T-cell **84**
 see also leukaemias; lymphomas
 normoblasts 6

O

oxygen–haemoglobin dissociation curves 42, 42

P

pancytopenia 125–127
 paroxysmal cold haemoglobinuria 37
 paroxysmal nocturnal haemoglobinuria (PNH) 36, 37, 127
 parvovirus B19 30, 32, 128–129
 pernicious anaemia 22–23, 24, 25
 personalized medicine 171
 petechiae 132, 132
 Philadelphia chromosome 111–112, 112, 163
 plasma cell myeloma 97–102, 98
 clinical features 97–99
 diagnosis 100–101
 laboratory findings 99–100, 99, 100
 staging 100
 treatment 101
 plasmacytoma 101–102
 plasmin 140
 platelet function analyser (PFA) 134
 platelets 5–6, 132–134
 aggregation studies 134
 failure of production 135
 function 6, **9**, 133
 abnormalities 137–138
 tests of 134
 increased splenic pooling 137
 physiology 133–134
 shortened survival 135–137
 transfusion 138, 157
 poikilocytes 17, 17
 polycythaemia 26, 113–114
 polymerase chain reaction (PCR) 166–167, 166
 post-transfusion purpura 137
 post-transplant lymphoproliferative disorder (PTLD) 61
 primary acquired sideroblastic anaemia 110
 primary myelofibrosis 114–115, 114, 115
 proerythroblasts 6, 7
 protein C 148, 148
 protein S 148, 148
 prothrombin allele G20210A 149
 prothrombin time (PT) 140, 141
 prothrombotic state 148
 pure red cell aplasia 30, 128–129
 purpura 106, 134
 post-transfusion 137
 thrombotic thrombocytopenic (TTP) 137
 see also immune thrombocytopenic purpura (ITP)
 pyruvate kinase deficiency 36

R

red cells 6–7, 14, 113
 abnormal cells 14

enzyme deficiencies 33–36
 erythropoiesis 6–7, 12–13
 function 7, **9**
 glucose metabolism 34
 mechanical damage 39–40, 40
 membrane 31
 defects causing haemolysis 30–33
 transfusion 152–154, **153**
 haemolytic reactions 158
 reduced intensity conditioning transplant 121
 Reed–Sternberg cells 71, 72, 85–86, 86
 refractory anaemia (RA) 110
 with excess blasts (RAEB) 110
 with ring sideroblasts (RARS) 110
 renal failure, plasma cell myeloma 98
 reticulocytes 7
 reticulocyte count 12, 28
 Rh blood group system 153, 154–155

S

Sanger sequencing 169, 169
 schistocytes 40
 secondary autoimmune thrombocytopenic purpura 137
 secondary polycythaemia 113
 semiquantitative PCR 168
 Serious Hazards of Transfusion (SHOT) report 157–158, 157
 Sézary syndrome 96
 Shwachman–Diamond syndrome 128
 sickle cell anaemia 47–53, 47, 50
 clinical manifestations **51**
 complications 50–52, 51, 52
 sickle cell trait 48
 sideroblastic anaemia 20, 20
 primary acquired (RARS) 110
 small lymphocytic lymphoma (SLL) 91, 92
 storage pool diseases 138
 streptokinase 140

T

T cells 65
 clonality studies 167, 167–168
 cytotoxic 8
 development 7–8, **8**, 66
 T helper (Th) cells 8

T-cell receptors (TCR) 7, 70, 167
 target cells 14
 thalassaemia 16, 43–47
 α -thalassaemia 43–45
 haemoglobin H disease 44, 44, 45
 Hb Bart's hydrops fetalis syndrome 44–45
 β -thalassaemia 45
 thalassaemia intermedia 46
 thalassaemia major 46–47
 thalassaemia minima 46
 thalassaemia minor 46
 thrombin 139
 thrombin time 140
 thrombocytopenia 132
 causes 134–137
 drug-induced 137
 see also immune thrombocytopenic purpura (ITP)
 thrombocytosis causes 115
 thrombophilia 148–149
 thrombopoietin (TPO) 5–6, 114
 thrombotic thrombocytopenic purpura (TTP) 137
 tissue factor (TF) 138–139, 138
 toxic granulation 57, 57
 toxoplasmosis 63
 transferrin 14, 19
 iron deficiency diagnosis 19
 transfusion *see* blood transfusion
 transfusion-related acute lung injury (TRALI) 160
 transfusion-transmitted infections (TTIs) 158–160

V

variant Creutzfeldt–Jakob disease (vCJD) 159
 venesection 16, 113, 114
 vitamin B12 21, **23**
 deficiency 14, 21–25, **23**
 biochemical pathways affected 22
 diagnosis 24–25, 24, 25
 manifestations 23–24, 24
 mechanisms 21–23, **23**
 vitamin K deficiency 145
 von Willebrand disease 144

W

Waldenström's macroglobulinaemia 92, 103
 warfarin 147